Please login to the form below

Not currently logged in
Email:
Password:

BMS and AZ gain approval for diabetes drug

The European Commission has granted marketing authorisation for Onglyza throughout the EU

The European Commission has granted marketing authorisation for the diabetes treatment Onglyza (saxagliptin) throughout the European Union(EU).

The once-daily 5 mg oral tablet dose is indicated in adult patients with type 2 diabetes mellitus in combination with other therapies (metformin, sulphonylurea, or thiazolidinedione) subject to certain criteria.

It was developed by Bristol-Myers Squibb(B-MS) and AstraZeneca(AZ) and is the first drug to be launched in Europe as part of the ongoing R&D collaboration between the two companies.

Béatrice Cazala, Bristol-Myers Squibb's president, Europe, and president, global commercialization, said: "The European Commission decision marks an important milestone in the alliance between Bristol-Myers Squibb and AstraZeneca."

Ulf Sather, AstraZeneca's regional vice president for Europe, commented: "Today's announcement is good news for those affected by type 2 diabetes and further demonstrates the commitment of AstraZeneca and Bristol-Myers Squibb to bring much needed options for the treatment of type 2 diabetes."

6th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics